MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Myeloma Multiple. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance. The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.
Primary outcome measures
- Response assessment (according to IMWG criteria) and / or disease progression (PD) [Time frame: 12 months after the start of therapy, in pre-neoplastic groups , only PD will be considered]
Secondary outcome measures (3)
- Response to treatment <VGPR (according to IMWG criteria) and/or disease progression (PD) [Time frame: From baseline to disease progression (PD), assessed up to 24 months.]
- Presence and/or absence of "secondary" tumor clone(s) [Time frame: From baseline to disease progression (PD), assessed up to 24 months.]
- Presence and/or absence of differences between baseline characteristics and progression features [Time frame: From baseline to disease progression (PD), assessed up to 24 months.]
Eligibility criteria
Inclusion criteria
- Age 18+
- Signed CI for study partecipation and personal data processing.
- Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM)
Exclusion criteria
- None
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- IRCCS AOU Policlinico Sant'Orsola — Bologna
Identifiers
NCT: NCT07582354 · MMAPPIN' · RC-2025-2797263